Abstract
The renal cell carcinoma (RCC) accounts for approximately 2-3% of human malignancies and, among urologic tumors, it is the most aggressive. The biological heterogeneity, drug resistance and side effects to chemotherapy are the biggest obstacles to effective treatment of RCC. Several molecules have been identified as responsible for the aggressive phenotype of this tumor, one being the NF-…